<DOC>
	<DOCNO>NCT02942329</DOCNO>
	<brief_summary>The purpose study observe preliminary explore efficacy safety combination Apatinib SHR-1210 regimen treat advance hepatocellular carcinoma gastric cancer . Apatinib small-molecule vascular endothelial growth factor receptor ( VEGFR ) tyrosine kinase inhibitor , similar vatalanib ( PTK787 ) , bind affinity 10 time vatalanib sorafenib . SHR-1210 humanized anti-PD-1 monoclonal antibody .</brief_summary>
	<brief_title>Exploratory Clinical Study Apatinib SHR-1210 Treating Advanced Hepatocellular Carcinoma Gastric Cancer</brief_title>
	<detailed_description>Patients receive apatinib 500mg orally daily SHR-1210 3mg/kg ( 200mg ) iv every 2 week . The efficacy safety observe .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion criterion 1 . Aged 1870 year old , gender . 2 . To confirm meet clinical diagnosis standard , histologically cytologically confirm hepatocellular carcinoma gastric cancer . Patients must diagnose advanced disease ( eligible surgical and/or locoregional therapy , metastatic disease ) , disease progress refractory standard therapy ( intolerant standard therapy , refuse standard therapy ) , lack effective treatment method . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . 4 . Life expectancy least 3 month . 5 . Patients must least 1 lesion measurable use RECIST v1.1 criterion . 6 . For patient advanced hepatocellular carcinoma , liver function status ChildPugh Class A B ( score &lt; =7 ) . 7 . Patients must adequate organ function ( without blood transfusion , without growth factor blood component support within 14 day enrollment ) determine : Hemoglobin ≥ 9 g/dL ; Absolute neutrophil count ( ANC ) ≥1.5×109/L ; Platelet count ≥ 75×109/L ( patient advance hepatocellular carcinoma ) , Platelet count ≥ 100×109/L ( patient advance gastric cancer ) ; serum albumin ≥2.8 g/dL ; serum total bilirubin ( TBIL ) ≤1.5 time upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5×upper limit normal ( ULN ) , subject liver metastasis , ALT AST≤5×ULN ; Calculated creatinine clearance ( CrCl ) &gt; 50 mL/min ( CockcroftGault formula use calculate CrCl ) . 8 . Females childbearing potential ( FOCBP ) , surgically sterile postmenopausal , must conduct pregnancy test ( serum urine ) within 7 day enrollment , must pregnant breastfeed woman . If result negative , must agree use adequate contraception experiment 3 month last administration test drug . And nonsterilized male sexually active must agree use adequate contraception experiment 3 month last administration test drug . 9 . Patients join study voluntarily , sign consent form , good compliance , comply followup . 1 . Patients must prior treatment SHR1210 PDL1 PD1 antagonist , must enrol phase III Study Apatinib After Systemic Therapy Patients With Hepatocellular Carcinoma . 2 . Patients active autoimmune disease history autoimmune disease , include limited following : hepatitis , pneumonitis , uveitis , colitis ( inflammatory bowel disease ) , hypophysitis , vasculitis , nephritis , hyperthyroidism , hypothyroidism , except subject vitiligo resolve childhood asthma/atopy . Asthma require intermittent use bronchodilator medical intervention also exclude . 3 . Concurrent medical condition require use immunosuppressive medication , immunosuppressive dos systemic absorbable topical corticosteroid . Doses &gt; 10 mg/day prednisone equivalent prohibit within 2 week study drug administration . Note : corticosteroid use purpose IV contrast allergy prophylaxis allow . 4 . Known history hypersensitivity component SHR1210 formulation , antibody formulation . 5 . Active central nervous system ( CNS ) metastases clinical symptom ( include cerebral edema , steroid requirement , progressive disease ) . Subjects brain meningeal metastases previously treat must clinically stable ( magnetic resonance image [ MRI ] least 4 week apart show evidence new enlarge metastasis ) discontinue immunosuppressive dos systemic steroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week study drug administration . 6 . Patients malignant tumor ( except cure skin basal cell carcinoma cervical carcinoma ) . 7 . Clinically significant cardiovascular cerebrovascular disease , include limit severe acute myocardial infarction within 6 month enrollment , unstable severe angina , coronary artery bypass surgery , Congestive heart failure ( New York heart association ( NYHA ) class &gt; 2 ) , ventricular arrhythmia need medical intervention , leave ventricular ejection fraction ( LVEF ) &lt; 50 % . 8 . Hypertension unable control within normal level follow treatment antihypertension agent ( within 3 month ) : systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg . 9 . Coagulation abnormality ( PT &gt; 16s、APTT &gt; 43s、TT &gt; 21s、Fbg &lt; 2g/L ) , bleed tendency receive thrombolytic anticoagulant therapy . 10 . Prior systemic chemotherapy , radiotherapy , immunotherapy , hormone therapy , surgery target therapy within 4 week ( Or 5 halflife drug , calculate longer ) study drug administration , unresolved AEs &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 ( exception stable chronic toxicity expect resolve ) . 11 . Patients clinical symptom ascites pleural effusion , need therapeutic puncture drainage . 12 . Previous digestive tract bleed history within 3 month evident gastrointestinal bleeding tendency , : esophageal varix , local active ulcerative lesion , gastric ulcer duodenal ulcer , ulcerous colitis , gastrointestinal disease portal hypertension resection tumor bleeding risk , etc . 13 . Patients previous serious hemorrhage ( bleed &gt; 30 ml within 3 month ) , haemoptysis ( &gt; 5 ml within 4 week ) thromboembolic event within 12 month ( include stroke event and/or transient ischemic attack ) . 14 . Active infection unexplained fever &gt; 38.5°C screen visit first schedule day dose ( discretion investigator , subject tumor fever may enrol ) . 15 . Previous experience abdomen fistula , gastrointestinal perforation , abdominal abscess within 4weeks . 16 . Objective evidence previous current pulmonary fibrosis history , interstitial pneumonia , pneumoconiosis , radiation pneumonitis , drugrelated pneumonia , pulmonary function damage seriously etc . 17 . History immunodeficiency include seropositivity human immunodeficiency virus ( HIV ) , acquire congenital immunedeficient disease , active hepatitis ( transaminase meet inclusion , hepatitis B virus ( HBV ) DNA ≥10⁴ /ml hepatitis C virus ( HCV ) RNA≥103 /ml high ) ; Chronic hepatitis B virus carrier HBV DNA＜2000 IU/ml ( &lt; 104/ml ) , must receive antiviral treatment throughout study . 18 . Participated clinical trial , finish clinical trial within 4 week . 19 . Patients may receive antitumor systemic chemotherapy study . 20 . Patients bone metastasis , receive Palliative radiotherapy ( radiotherapy area &gt; 5 % marrow area ) . 21 . Patients may receive vaccination study , previous vaccination within 4 week . 22 . Mental disorder history , psychotropic drug abuse history . 23 . Any medical , psychiatric , social condition deem investigator likely interfere subject 's right , safety , welfare , ability sign inform consent , cooperate , participate study would interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>humanize anti-PD-1 monoclonal antibody</keyword>
	<keyword>apatinib</keyword>
	<keyword>Gastric Neoplasms</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Cancer Stomach</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Liver Cancer , Adult</keyword>
	<keyword>Liver Cell Carcinoma</keyword>
</DOC>